UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

☒  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended: February 29, 2020

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

Commission File Number: 000-52759

 

BESPOKE EXTRACTS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada		20-4743354
(State or other jurisdiction  of incorporation)		(IRS Employer  Identification No.)

 

323 Sunny Isles Boulevard, Suite 700

Sunny Isles Beach, FL 33160

(Address of principal executive offices)

 

855-633-3738

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months, and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒

 

As of April 8, 2020, there were 110,389,621 shares outstanding of the registrant’s common stock, par value $0.001.

 

 

 

TABLE OF CONTENTS

 

		Page No.
PART I - FINANCIAL INFORMATION		1
Item 1.	Financial Statements	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19
Item 4	Controls and Procedures	19
PART II - OTHER INFORMATION		20
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	20
Item 5.	Other Information	20
Item 6.	Exhibits	20

 

 

PART I

 

 

Item 1. Financial Statements. 

 

Bespoke Extracts, Inc.

Condensed Balance Sheets

 

		February 29,				August 31,
		2020				2019
		(Unaudited)
Assets
Current assets
Cash		$	45,157			$	10,343
Accounts receivable, net			3,636				6,452
Prepaid expense			18,000				17,637
Inventory, net			1,264				3,171
Total current assets			68,057				37,603
Domain names, net of amortization of $10,061 and $8,364, respectively			34,552				41,821
Total assets		$	102,609			$	79,424
Liabilities and Stockholders’ Deficit
Current liabilities
Accounts payable and accrued liabilities		$	96,988			$	111,056
Convertible notes - net of unamortized discounts $242,187 and $0, respectively			257,813				-
Total current liabilities			354,801				111,056
Commitments and contingencies (Note 6)
Stockholders’ Deficit
Preferred Stock, $0.001 par value, 50,000,000 authorized shares; 1 share issued and outstanding as of February 29, 2020 and 0 shares issued and outstanding at August 31, 2019, respectively
Series A Convertible Preferred Stock, $0.001 par value, 1,000 shares designated; no shares issued and outstanding as of February 29, 2020 and August 31, 2019, respectively			-				-
Series B Convertible Preferred Stock, $1 par value, 1  authorized share;  1 shares issued and outstanding as of February 29, 2020 and  0 shares issued and outstanding at August 31, 2019, respectively			1				-
Common stock, $0.001 par value: 800,000,000 authorized; 110,388,426 and 78,155,093 shares issued and outstanding as of February 29, 2020 and August 31, 2019, respectively			110,389				78,156
Additional paid-in capital			14,796,446				13,950,095
Common stock payable			76,000				76,000
Accumulated deficit			(15,235,028	)			(14,135,883	)
Total stockholders’ deficit			(252,192	)			(31,632	)
Total liabilities and stockholders’ deficit		$	102,609			$	79,424

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

Bespoke Extracts, Inc.

Condensed Statements of Operations

Unaudited

 

		For the three months ended								For the Six months ended
		February 29,				February 28,				February 29,				February 28,
		2020				2019				2020				2019
Sales		$	-			$	12,509			$	1,739			$	53,940
Cost of products sold			-				4,280				1,087				15,888
Gross Profit			-				8,229				652				38,052
Operating expenses:
Selling, general and administrative expenses			190,928				239,560				432,430				(3,838,781	)
Professional fees			93,411				68,488				148,786				106,483
Consulting			32,000				59,000				133,500				114,500
Amortization expense and impairment of domain name			1,150				837				1,986				1,673
Total operating expenses			317,489				367,885				716,702				(3,616,125	)
Income / (Loss) from operations			(317,489	)			(359,656	)			(716,050	)			3,654,177
Other expense
Financing common share expense			-				-				-				(76,000	)
Loss on settlement of debt			(89,595	)			-				(89,595	)			-
Interest expense and amortization of debt discount			(275,656	)			(148,879	)			(293,500	)			(232,912	)
Total other expense			(365,251	)			(148,879	)			(383,095	)			(308,912	)
Income / (Loss) before income tax			(682,740	)			(508,535	)			(1,099,145	)			3,345,265
Provision for income tax			-				-				-				-
Net Income / (Loss)		$	(682,740	)		$	(508,535	)		$	(1,099,145	)		$	3,345,265
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and Diluted			109,055,093				52,133,342				97,749,658				48,551,147
NET INCOME / (LOSS) PER COMMON SHARE OUTSTANDING
Basic and Diluted		$	(0.01	)		$	(0.01	)		$	(0.01	)		$	0.07

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

  

 

Bespoke Extracts, Inc.

Condensed Statements of Cash Flows

Unaudited

 

		For the Six months ended
		February 29,				February 28,
		2020				2019
Cash flows from operating activities
Net Income / (Loss)		$	(1,099,145	)		$	3,345,265
Adjustments to reconcile net income (loss) to net cash used in operating activities
Amortization and impairment expense of domain names			1,986				1,672
Amortization of debt discounts			293,500				190,162
Bad debt expense			2,981				-
Loss on settlement of debt			89,595				-
Gain on forfeited unvested employee stock award (net of cash paid of $1,600)			-				(2,440,768	)
Option and warrant expense			316,585				(1,629,580	)
Common stock issued for services			40,500				120,000
Make good common share expense			-				76,000
Changes in operating assets and liabilities:
Accounts receivable			(165	)			(4,009	)
Inventory			(363	)			7,673
Prepaid expense			1,907				3,412
Accounts payable and accrued liabilities			9,933				73,492
Net Cash used in operating activities			(342,686	)			(256,681	)
Cash flow from financing activities
Proceeds from the issuance of convertible debt			400,000				-
Proceeds from exercise of warrants for cash			-				2,000
Repayment of debt			(120,000	)			-
Repurchase of common stock			(27,500	)			-
Sale of common stock			125,000				285,000
Net cash provided by financing activities			377,500				287,000
Net increase in cash and cash equivalents			34,814				30,319
Cash and cash equivalents at beginning of period			10,343				79,784
Cash and cash equivalents at end of period		$	45,157			$	110,103
Supplemental disclosure of cash flow information
Cash paid for interest		$	-			$	-
Cash paid for income taxes		$	-			$	-
Noncash investing and financing activities:
Discount due beneficial conversion feature		$	281,300			$	-
Stock issued with convertible debt		$	118,700			$	-
Preferred stock issued for the conversion of accrued salary		$	24,000			$	-
Assignment of URL for settlement of debt		$	5,282			$	-

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

Bespoke Extracts, Inc.

Condensed Statement of Stockholders Equity / (Deficit)

For The Three and Six Months Ended February 29, 2020 and February 28, 2019

Unaudited

 

		Series A								Series B
		Preferred				Preferred				Preferred				Preferred				Common				Common								Common
		Shares				Par				Shares				Par				Shares				Par								Stock				Accumulated
		Outstanding				Amount				Outstanding				Amount				Outstanding				Amount				APIC				Payable				Deficit				Total
Balance November 30, 2018 (Unaudited)			—			$	—				—			$	—				49,902,712			$	49,903			$	12,238,907			$	76,000			$	(12,862,844	)		$	(498,034	)
Sale of common stock			-				-				-				-				6,966,667				6,967				158,033				-				-				165,000
Options and warrant expense			-				-				-				-				-				-				171,946				-				-				171,946
Net loss for the three months ended February 28, 2019			-				-				-				-				-				-				-				-				(508,535	)			(508,535	)
Balance February 28. 2019 (Unaudited)			—			$	—				—			$	—				56,869,379			$	56,870			$	12,568,886			$	76,000			$	(13,371,379	)		$	(669,623	)
Balance November 30, 2019  (Unaudited)			—			$	—				1			$	1				105,388,426			$	105,389			$	14,341,227			$	76,000			$	(14,552,288	)		$	(29,671	)
Option and warrant expense			-				-				-				-												160,219				-				-				160,219
Common stock issued with debt			-				-				-				-				5,000,000				5,000				50,000				-				-				55,000
Beneficial conversion feature on convertible debt			-				-				-				-				-				-				245,000				-				-				245,000
Net loss for the three months ended February 29, 2020			-				-				-				-				-				-				-				-				(682,740	)			(682,740	)
Balance February 29. 2020 (Unaudited)			—			$	—				1			$	1				110,388,426			$	110,389			$	14,796,446			$	76,000			$	(15,235,028	)		$	(252,192	)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

Bespoke Extracts, Inc.

Condensed Statement of Stockholders Equity / (Deficit)

For The Three and Six Months Ended February 29, 2020 and February 28, 2019

Unaudited

 

		Series A								Series B
		Preferred				Preferred				Preferred				Preferred				Common				Common								Common
		Shares				Par				Shares				Par				Shares				Par								Stock				Accumulated
		Outstanding				Amount				Outstanding				Amount				Outstanding				Amount				APIC				Payable				Deficit				Total
Balance August 31, 2018			—			$	—				—			$	—				42,902,712			$	42,903			$	16,246,201			$	-			$	(16,716,644	)		$	(427,540	)
Sale of common stock			-				-				-				-				8,966,667				8,967				276,033				-				-				285,000
Forfeiture of stock issued through warrant exercise, net of cash paid			-				-				-				-				(16,000,000	)			(16,000	)			(2,424,768	)			-				-				(2,440,768	)
Common stock issued for the exercise of warrants			-				-				-				-				20,000,000				20,000				(18,000	)			-				-				2,000
Common stock issued  for services			-				-				-				-				1,000,000				1,000				119,000				-				-				120,000
Option and warrant expense			-				-				-				-				-				-				(1,629,580	)			-				-				(1,629,580	)
Financing common share expense			-				-				-				-				-				-				-				76,000				-				76,000
Net income for the six months ended February 28, 2019			-				-				-				-				-				-				-				-				3,345,265				3,345,265
Balance February 28, 2019 (unaudited)			—			$	—				—			$	—				56,869,379			$	56,870			$	12,568,886			$	76,000			$	(13,371,379	)		$	(669,623	)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

Bespoke Extracts, Inc.

Condensed Statement of Stockholders Equity / (Deficit)

For The Three and Six Months Ended February 29, 2020 and February 28, 2019

Unaudited

 

		Series A								Series B
		Preferred				Preferred				Preferred				Preferred				Common				Common								Common
		Shares				Par				Shares				Par				Shares				Par								Stock				Accumulated
		Outstanding				Amount				Outstanding				Amount				Outstanding				Amount				APIC				Payable				Deficit				Total
Balance August 31, 2019			—			$	—				—			$	-				78,155,093			$	78,156			$	13,950,095			$	76,000			$	(14,135,883	)		$	(31,632	)
Preferred stock issued for the conversion of accrued salary			-				-				1				1				-				-				23,999				-				-				24,000
Sale of common stock			-				-				-				-				20,833,333				20,833				104,167				-				-				125,000
Common stock issued for services			-				-				-				-				4,500,000				4,500				36,000				-				-				40,500
Warrant expense			-				-				-				-				-				-				316,585				-				-				316,585
Common stock issued with debt			-				-				-				-				9,900,000				9,900				108,800				-				-				118,700
Repurchase of common stock			-				-				-				-				(3,000,000	)			(3,000	)			(24,500	)			-				-				(27,500	)
Beneficial conversion feature			-				-				-				-				-				-				281,300				-				-				281,300
Net loss for the six  months ended February 29, 2020			-				-				-				-				-				-				-				-				(1,099,145	)			(1,099,145	)
Balance February 29, 2020 (Unaudited)			—			$	—				1			$	1				110,388,426			$	110,389			$	14,796,446			$	76,000			$	(15,235,028	)		$	(252,192	)

 

The accompanying notes are an integral part of these unaudited condensed financial statements.

 

 

Bespoke Extracts, Inc.

Notes to Condensed Financial Statements

Unaudited

 

1. NATURE OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND GOING CONCERN  

 

Nature of Business Operations

 

Bespoke Extracts, Inc. (the “Company”) is a Nevada corporation focused on marketing and selling a proprietary line of premium, quality, all natural CBD products in the forms of tinctures, capsules, drops and edibles for the nutraceutical and veterinary markets, which it introduced in mid-2018. Produced using pure, all natural, zero-THC phytocannabinoid-rich (“PCR”) hemp-derived isolate, the Company markets its products as dietary supplements through its retail ecommerce store found at www.bespokeextracts.com. In the future, the Company also intends to sell its products through wholesale channels.

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim information and with the instructions to Form 10-Q and Regulation S-K. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments consisting of a normal and recurring nature considered necessary for a fair presentation have been included. Operating results for the six-month period ended February 29, 2020 may not necessarily be indicative of the results that may be expected for the year ending August 31, 2020.

 

For further information, refer to the Company's financial statements and footnotes thereto included in the Annual Report on Form 10-K for the year ended August 31, 2019.

 

Certain prior period amounts have been reclassified to conform to current period presentation.

  

Going Concern

 

The accompanying financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations, a working capital deficit and an accumulated deficit for the six months ended and as of February 29, 2020. This raises substantial doubt about our ability to continue as a going concern.

 

The Company’s ability to continue as a going concern is dependent upon the Company generating profitable operations in the future and/or obtaining the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. There is no assurance that this series of events will be satisfactorily completed. The accompanying financial statements do not contain any adjustments that may result from the outcome of this uncertainty.

  

Use of Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements and accompanying notes. Actual results could differ from those estimates.

 

Cash and Cash Equivalents

 

Cash and cash equivalents include all highly liquid investments with original maturities of three months or less at the time of purchase. At February 29, 2020 and August 31, 2019, the Company did not have any cash equivalents.

  

 

Fair Value of Financial Instruments

 

The carrying amounts of cash, accounts receivable, prepaid expenses and other assets, accounts payable, accrued liabilities and convertible note payable approximate their fair values as of February 29, 2020 and August 31, 2019, respectively, because of their short-term natures.

 

Accounts Receivable

 

Accounts receivable are recorded at fair value on the date revenue is recognized. The Company provides allowances for doubtful accounts for estimated losses resulting from the inability of its customers to repay their obligation. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to repay, additional allowances may be required. The Company provides for potential uncollectible accounts receivable based on specific customer identification and historical collection experience adjusted for existing market conditions. If market conditions decline, actual collection experience may not meet expectations and may result in decreased cash flows and increased bad debt expense.

 

The policy for determining past due status is based on the contractual payment terms of each customer, which are generally net 30 or net 60 days. Once collection efforts by the Company and its collection agency are exhausted, the determination for charging off uncollectible receivables is made. At February 29, 2020 and August 31, 2019 the Company has recorded an allowance for doubtful accounts of $2,981 and $0, respectively.

 

Inventory

 

Inventories are stated at the lower of cost or net realizable value.  Cost is determined by the first-in, first-out basis and net realizable value. Net realizable value is defined as sales price less cost of completion, disposition and transportation and a normal profit margin. As of February 29, 2020 and August 31, 2019, inventory amounted to $1,264 and $3,171, respectively, which consisted of finished goods. During the year ended August 31, 2019 the Company reserved $52,332 for slow moving inventory. No additional reserve was recorded during the six months ended February 29, 2020.

  

Revenue Recognition

 

Net revenue is measured based on the amount of consideration that we expect to receive, reduced by discounts and estimates for credits and returns (calculated based upon previous experience and management’s evaluation). Outbound shipping charged to customers is recognized at the time the related merchandise revenues are recognized and are included in net revenues. Inbound and outbound shipping and delivery costs are included in cost of revenues. Net revenues exclude sales and other similar taxes collected from customers.

 

Our products are sold through our online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due on the date of shipment. The Company offers a 14 day return policy on sales.

   

Stock Option Plans

 

Stock options and warrants issued to consultants and other non-employees as compensation for services provided to the Company are accounted for based on the fair value of the services provided or the estimated fair market value of the option or warrant, whichever is more reliably measurable in accordance with, and FASB ASC 718, Compensation-Stock Compensation, including related amendments and interpretations. The related expense is recognized over the period the services are provided. Stock option compensation expense has been recognized as a component general and administrative expenses in the accompanying financial statements for the three and six months ended February 29, 2020 and February 28, 2019.

  

 

Net Income / Loss per Share

 

Basic income / loss per share amounts are computed based on net income / loss divided by the weighted average number of common shares outstanding. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock. The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. The effect of 3,450,000 warrants and 1,200,000 options is anti-dilutive for the three and six months end February 29, 2020. The effect of 3,490,000 warrants and 1,200,000 options is anti-dilutive for the three and six months ended February 28, 2019.

 

Recent Accounting Pronouncements

 

In February 2016, the FASB issued ASU 2016-02, Leases, which will amend current lease accounting to require lessees to recognize (i) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (ii) a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. ASU 2016-02 does not significantly change lease accounting requirements applicable to lessors; however, certain changes were made to align, where necessary, lessor accounting with the lessee accounting model. This standard was effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years.

 

The adoption of ASU 2016-02 did not have an impact on our balance sheet, results of operations or balance sheets as we currently do not have any long term corporate office and equipment leases.

 

2. ASSET PURCHASE AGREEMENT

 

On February 21, 2017, the Company purchased all right, title, interest and goodwill in or associated with certain domain names set forth in an asset purchase agreement for a total of $20,185 in cash and 200,000 shares of the Company’s common stock valued at $30,000. For the three and six months ended February 29, 2020 amortization expense amounted to $861 and $1,697, respectively. For the three and six months ended February 28, 2019 amortization expense amounted to $837 and $1,672, respectively. The domain names are being amortized over a 15 year period. During the three and six months ended February 29, 2020, the Company recorded an impairment expense of $289 for expired domain names.

 

On December 24, 2019, the Company repaid a note holder $120,000, and transferred certain URLs valued at $5,282 to the holder (See note 3.)

 

3. CONVERTIBLE NOTE PAYABLE

  

On November 6, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which, the Company issued and sold to the investor an original issue discount convertible debenture (which was amended and restated on November 11, 2019) in the principal amount of $200,000, for a purchase price of $100,000, resulting in an original issue discount of $100,000. The Company also issued to the investor 4,900,000 shares of common stock valued at $63,700 ($0.013 per share). As amended, the debenture had a maturity date of August 1, 2020 and was convertible into shares of common stock of the Company at a conversion price of $0.006, provided that, if the Company failed to repay the debenture upon maturity, the conversion price would be reduced to $0.001 (subject to adjustment for stock splits, stock dividends and similar transactions) and the debenture would bear interest at the rate of 9% per year. The Company recorded beneficial conversion of $36,300 due to the conversion feature. The debenture could not be converted to common stock to the extent such conversion would result in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock. The Company’s obligation to repay the debenture upon maturity was secured by a security interest in the Company’s URLs pursuant to a security agreement between the Company and the investor.

 

 

On December 24, 2019, the Company entered into an agreement (the “Repayment Agreement”) with the holder of the amended and restated original issue discount convertible debenture issued by the Company on November 11, 2019, in the original principal amount of $200,000 (the “November 2019 Debenture”). Pursuant to the Repayment Agreement, the Company paid the holder $120,000, and transferred certain URLs valued at $5,282 to the holder, and the November 2019 Debenture was deemed paid in full. The amortization of debt discount of $17,843 and $35,687, respectively were recorded during the three and six months ended February 29, 2020. The Company recognized a loss on settlement of debt of $89,595 during the three and six months ended February 29, 2020.

  

On December 24, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which, the Company issued and sold to the investor an original issue discount convertible debenture in the principal amount of $500,000, for a purchase price of $300,000. The Company also issued to the investor 5,000,000 shares of common stock valued at $55,000 ($.005 per share). The Company recorded beneficial conversion of $245,000 due to the conversion feature. The debenture may not be converted to common stock to the extent such conversion would result in the holder beneficially owning more than 4.99% of the Company’s outstanding common stock. The debenture matures April 30, 2020 and is convertible into shares of common stock of the Company at a conversion price of $0.001, except that, if the Company fails to repay the debenture upon maturity, the conversion price will be reduced to $0.0004 (subject to adjustment for stock splits, stock dividends, and similar transactions) and the debenture will bear interest at the rate of 9% per year. The Company’s obligation to repay the debenture upon maturity is secured by a security interest in the Company’s inventory pursuant to a security agreement between the Company and the investor. For the three and six months ended February 29, 2020 the Company recorded amortization of debt discount of $257,813.

 

4. EQUITY

 

Common Stock and Preferred Stock

 

The Company has authorized capital of 800,000,000 shares of common stock with a par value of $0.001, and 50,000,000 shares of preferred stock with a par value of $0.001. 1,000 shares of preferred stock are designated as Series A Convertible Preferred Stock. No shares of Series A Preferred Stock are issued and outstanding as of February 29, 2020 and August 31, 2019, respectively. 1 share of preferred stock is designated Series B Preferred Stock. 1 share and 0 shares of Series B Preferred Stock are issued and outstanding as of February 29, 2020 and August 31, 2019, respectively. The Series B Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series B Preferred Stock at any time for a redemption price equal to the stated value. The Series B Preferred does not provide the holder with any dividend rights or any liquidation rights, and is not convertible to common stock.

 

On October 30, 2018, the Company entered into an employment agreement with Niquana Noel pursuant to which Ms. Noel will serve as the Company’s Chief Executive Officer and president for a term of four years, unless earlier terminated pursuant to the terms of the employment agreement. Pursuant to the terms of the employment agreement, Ms. Noel’s annual salary is $96,000 and she received a warrant to purchase up to 20,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share. Ms. Noel exercised the warrant for $2,000 and was issued the 20,000,000 shares on October 31, 2018. The shares received upon the exercise of the warrants are subject to forfeiture over a service period of four years. See “Warrants” below. 

 

Pursuant to a securities purchase agreement entered into on June 6, 2018 the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser will be equal to $50,000 divided by lower financing price. As of February 29, 2020, the Company was obligated to issue 500,000 shares of common stock valued at $76,000.

   

On October 3, 2019, the Company entered into a letter agreement with Niquana Noel, the Company’s chief executive officer. Pursuant to the agreement, Ms. Noel exchanged $24,000 in accrued but unpaid compensation owed to her by the Company for one share of newly created Series B Preferred Stock of the Company. Ms. Noel subsequently exchanged this one share of Series B Preferred for 1 one share of newly created Series C Preferred Stock. See Note 8.

 

In connection with the letter agreement, on October 3, 2019, the Company filed a Certificate of Designation of Series B Preferred Stock with the Secretary of State of Nevada. Pursuant to the Certificate of Designation, the Company designated one share of its preferred stock as Series B Preferred Stock. See “Common Stock and Preferred Stock” above.

 

On October 14, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor pursuant to which the Company issued and sold to the investor 20,833,333 shares of common stock for a purchase price of $125,000.

 

In November 2019, 3,000,000 shares of common stock were returned to the Company for cancellation and the Company paid $27,500 in connection with a settlement agreement.

  

 

On November 6, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which, the Company issued and sold to the investor an original issue discount convertible debenture (which was amended and restated on November 11, 2019) in the principal amount of $200,000, for a purchase price of $100,000, resulting in an original issue discount of $100,000. The Company also issued to the investor 4,900,000 shares of common stock valued at $63,700, ($0.013 per share). See Note 3.

  

Effective November 11, 2019, the Company issued 4,500,000 shares of common stock pursuant to a consulting agreement valued at $40,500 ($0.009 per share).

 

On December 24, 2019, the Company entered into and closed a securities purchase agreement with an accredited investor, pursuant to which, the Company issued and sold to the investor an original issue discount convertible debenture in the principal amount of $500,000, for a purchase price of $300,000. The Company also issued to the investor 5,000,000 shares of common stock valued at $55,000 ($.005 per share).

 

Warrants 

 

On May 22, 2017, the Company entered into an employment agreement with Marc Yahr to serve as President and Chief Executive Officer of the Company for a term of three years, unless earlier terminated pursuant to the terms of the employment agreement. Pursuant to the terms of the employment agreement, Mr. Yahr received a warrant to purchase up to 20,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share. The warrants were exercised in full on May 31, 2017; however, the 20,000,000 shares of the Company’s common stock were not issued to Mr. Yahr until June 10, 2017. The shares received upon the exercise of the warrants were subject to forfeiture over a service period of three years. The fair value of the award was determined to be $10,998,105 which will be recognized as compensation expense over the three year service period.  Effective October 30, 2018, Marc Yahr resigned from all positions with the Company including as President and Chief Executive Officer of the Company (except as director, which he resigned as on November 25, 2018). Pursuant to the agreement, Mr. Yahr agreed to return 80% of the warrant shares to the Company if he served as CEO of the Company pursuant to the terms and conditions of the employment agreement for a period of more than 12 months but less than 18 months. Therefore, 16,000,000 shares of common stock were forfeited to the Company, and the Company recognized a gain on the forfeited common shares of ($2,440,768) net of $1,600 paid by the Company during the six months ended February 28, 2019. As of February 28, 2019, $0 remains to be expensed over the remaining vesting period.

 

On March 2, 2018 the Company entered into a management agreement with Global Corporate Management, LLC. Pursuant to this agreement, the Company agreed to pay $4,000 and to issue 150,000 common stock purchase warrants per month (an aggregate of 3,600,000 warrants) with an exercise price of $0.50, exercisable commencing six months after issuance for a period of 5 years.  During the three and six months ended February 29, 2020 the Company recognized a gain of $0 and $(3,378), respectively due to a remeasurement of this nonemployee award.   During the three and six months ended February 28, 2019 the Company recognized a (gain) / expense of $(8,363) and $(1,273,049), respectively due to a remeasurement of this nonemployee award.

  

On April 16, 2018, the Company entered into a consulting agreement with Dr. David Hellman for marketing and promotion services. The term is 1 year with payment of 50,000 warrants each month to purchase common stock with an exercise price of $0.60. However, if the consultant generates more than $10,000 in monthly sales, the warrants will have an exercise price of $.30, and if the consultant generates more than $20,000 in monthly sales, the warrants may be exchanged in “cashless exercise”. Additionally, the Company shall pay 10% of retail sales and 5% of wholesale sales. On July 11, 2018 the Company terminated the agreement. On August 1, 2018 the Company entered into a new consulting agreement with Dr. Hellman. The term is 1 year with payment of 60,000 warrants each month to purchase common stock with an exercise price of $0.60. The warrants may be exercised on a cashless basis. A total of $256,038 warrant expense in relation to this award was recognized during the year ended August 31, 2018. During the three and six months ended February 29, 2020 the Company recognized an expense / gain of $179 and ($1,905), respectively due to a remeasurement of this nonemployee award.  The warrants may be exercised on a cashless basis.  During the three and months ended February 28, 2019 the Company recognized a (gain) / expense of $8,225 and $(107,618), respectively due to a remeasurement of this nonemployee award.

 

On October 30, 2018, the Company entered into an employment agreement with Niquana Noel pursuant to which Ms. Noel will serve as the Company’s Chief Executive Officer and president for a term of four years, unless earlier terminated pursuant to the terms of the employment agreement. Pursuant to the terms of the employment agreement, Ms. Noel’s annual salary is $96,000 and she received a warrant to purchase up to 20,000,000 shares of the Company’s common stock at an exercise price of $0.0001 per share. Ms. Noel exercised the warrant and was issued the 20,000,000 shares on October 31, 2018. The fair value of this award was determined to be $2,598,138 of which $160,040 and $321,868 and was recognized during the three and six months ended February 29, 2020. The fair value of this award was determined to be $2,598,138 of which $162,384 and $216,512 was recognized during the three and six months ended February 28, 2019, respectively

 

 

Unamortized expense at February 29, 2020 is $1,733,871 and as of August 31, 2019 is $2,055,748. The shares received upon the exercise of the warrants are subject to forfeiture over a service period of four years. The shares will be required to be returned to the Company as follows and the Company accounts for forfeitures when they occur:

 

Ms. Noel would have been required to return 80% of the common stock to the Company if she was not serving as Chief Executive Officer of the Company pursuant to the terms and conditions of her employment agreement as of October 30, 2019 (the first anniversary of the employment agreement);

  

Ms. Noel shall return 60% of the common stock to the Company if she is not serving as the Chief Executive Officer of the Company pursuant to the terms and conditions of the employment agreement as of the second anniversary of the employment agreement (October 30, 2020);

 

Ms. Noel shall return 40% of the common stock to the Company if she is not serving as Chief Executive Officer of the Company pursuant to the terms and conditions of the employment agreement as of the third anniversary of the employment agreement (October 30, 2021);

 

Ms. Noel shall return 20% of the common stock to the Company if she is not serving as the Chief Executive Officer of the Company pursuant to the terms and conditions of the employment agreement as of the fourth anniversary of the employment agreement (October 30, 2022);

 

The following table summarizes the warrant activities during the six months ended February 29, 2020:

 

		Number of Warrants				Weighted- Average Price Per Share
Outstanding at August 31, 2019			3,330,000			$	0.56
Granted			120,000				0.60
Cancelled or expired			-				-
Exercised			-				-
Outstanding at February 29, 2020			3,450,000			$	0.56
Exercisable at February 29, 2020			3,450,000			$	0.56
Intrinsic value at February 29, 2020						$	-

 

The fair value of the warrants was estimated using the Black-Scholes option pricing model and the following range of assumptions:

 

		Grant Date and Re-measurement Date
For the six month ended February 29, 2020
Risk-free interest rate at grant date		1.30% - 1.62%
Expected stock price volatility		314% - 394%
Expected dividend payout		-
Expected life (in years)		2.50 – 4.50

 

 

OPTIONS

 

On July 26, 2017 the Company granted a nonemployee options to purchase 2,200,000 shares of common stock. The options have a three year term. 1,000,000 options were immediately exercisable on the date of issuance with an exercise price of $0.001 and the remaining 1,200,000 options vest over a period of four (4) semiannual installments or every six (6) months until July 26, 2019 at an exercise price of $1.00. As of February 29, 2020 all the options were fully vested..  During the three and six months ended February 28, 2019 the Company recognized a gain of $(7,419) and $(376,250), respectively.

 

		Number of Options				Weighted- Average Price Per Share
Outstanding at August 31, 2019			1,200,000			$	1.00
Granted			-				-
Canceled or expired			-				-
Exercised			-				-
Outstanding at February 29, 2020			1,200,000			$	1.00
Exercisable at February 29, 2020			1,200,000			$	1.00
Intrinsic value at February 29, 2020						$	-

 

5. RELATED PARTY TRANSACTIONS

 

 On May 22, 2017, the Company entered into an employment agreement with Marc Yahr to serve as President and Chief Executive Officer of the Company for a term of three years, unless earlier terminated pursuant to the terms of the employment agreement. See Note 4.

  

On October 30, 2018, the Company entered into an employment agreement with Niquana Noel pursuant to which Ms. Noel will serve as the Company’s Chief Executive Officer and president for a term of four years, unless earlier terminated pursuant to the terms of the employment agreement. See Note 4.

 

6. COMMITMENTS AND CONTINGENCIES

  

On April 16, 2018 the Company entered into a consulting agreement with Dr. David Hellman for marketing and promotion services. The term is 1 year with payment of 50,000 warrants to purchase common stock with an exercise price of $0.60. However, if the consultant generates more than $10,000 in monthly sales, the warrants will have an exercise price of $0.30, and if the consultant generates more than $20,000 in monthly sales, the warrants may be exchanged in “cashless exercise”. Additionally, the Company agreed to pay to the consultant 10% of retail sales and 5% of wholesale sales. On July 11, 2018 the Company terminated the agreement. On August 1, 2018 the Company entered into a new consulting agreement with Dr. Hellman. The term is 1 year with payment of 60,000 warrants to purchase common stock with an exercise price of $0.60. The warrants may be exercised on a cashless basis. (See note 4). As of February 29, 2020 no commission have been earned under this agreement. As of February 29, 2020 the agreement has expired.  

 

Pursuant to a securities purchase agreement entered into on June 6, 2018 the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser will be equal to $50,000 divided by lower financing price. As of February 29, 2020 and August 31, 2019 the Company was obligated to issue 500,000 shares of common stock valued at $76,000 which is included in the common stock payable in the accompanying balance sheet.

   

On July 19, 2019 the Company entered into a non-binding preliminary term sheet with Cannasaver Corp. (“Cannasaver”). The term sheet contemplates that the Company will acquire Cannasaver for aggregate consideration of $25,000,000, 80% of which will be in the form of common stock of the Company, and the remaining 20% of which will be in cash, it being recognized that the Company will need to raise such funds from investors. The completion of this acquisition will be subject to entering into definitive agreements and the satisfaction of customary closing conditions, and there is no assurance such transaction will be completed. Cannasaver is partially owned by Lyle Hauser, who is a former significant stockholder of the Company and is an adviser to the Company. As of the date of this report the transaction has not been consummated.

 

  

7. MAJOR CUSTOMERS

 

There are concentrations of credit risk with respect to accounts receivables due to the amounts owed by one customer at August 31, 2019 whose balance represented approximately 28%, of total accounts receivables. As of February 29, 2020, no customer amounted to over 10% of accounts receivable. During the three and six months ended February 29, 2020, no individual customer amounted to over 10% of total sales. During the three and six months ended February 28, 2019, no individual customer amounted to over 10% of total sales. The loss of business from one or a combination of the Company’s significant customers, or an unexpected deterioration in their financial condition, could adversely affect the Company’s operations.

 

8. SUBSEQUENT EVENTS 

 

On March 25, 2020, Company entered into a letter agreement with Niquana Noel, the Company’s chief executive officer. Pursuant to the agreement, Ms. Noel exchanged 1 share of Series B Preferred Stock of the Company for one share of newly created Series C Preferred Stock of the Company.

 

In connection with the letter agreement, on March 25, 2020, the Company filed a Certificate of Designation of Series C Preferred Stock with the Secretary of State of Nevada. Pursuant to the Certificate of Designation, the Company designated one share of its preferred stock as Series C Preferred Stock. The Series C Preferred Stock has a stated value of $24,000 and entitles the holder to 51% of the total voting power of the Company’s stockholders. The Company may, in its sole discretion, redeem the Series C Preferred Stock at any time for a redemption price equal to the stated value. The Series C Preferred Stock has a liquidation preference equal to the stated value, does not provide the holder with any dividend rights and is not convertible to common stock.

 

The COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management, and professional advisors. These factors, in turn, may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable terms, or at all.

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

We and our representatives may from time to time make written or oral statements that are “forward-looking,” including statements contained in this Quarterly Report and other filings with the SEC, reports to our stockholders and news releases. All statements that express expectations, estimates, forecasts or projections are forward-looking statements. In addition, other written or oral statements which constitute forward-looking statements may be made by us or on our behalf. Words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “project,” “forecast,” “may,” “should,” and variations of such words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in or suggested by such forward-looking statements. We undertake no obligation to update or revise any of the forward-looking statements after the date of this Quarterly Report to conform forward-looking statements to actual results, except as may be required under applicable law. Important factors on which such statements are based are assumptions concerning uncertainties, including but not limited to, uncertainties associated with the following:

 

●

Inadequate capital and barriers to raising the additional capital or to obtaining the financing needed to implement our business plans;

 

●

Our failure to earn revenues or profits;

 

●

Inadequate capital to continue business;

 

●

Volatility, lack of liquidity or decline of our stock price;

 

●

Potential fluctuation in quarterly results;

 

●

Rapid and significant changes in markets;

 

●

Insufficient revenues to cover operating costs;

 

●

The effect of the COVID-19 pandemic on our operations, including as it may limit access to our facilities, customers, management, and professional advisors, and negatively impact demand for our products, and ability to raise capital on acceptable terms or at all.

 

The following discussion should be read in conjunction with the financial statements and the notes thereto which are included in this Quarterly Report.

 

Overview

 

We were incorporated in the State of Colorado on July 29, 1988 under the name Cine-Source Entertainment, Inc. On April 27, 2004, the Company changed its name to First Quantum Ventures, Inc. On April 13, 2006, the Company changed its name to First Quantum Ventures, Inc., and on May 5, 2006, the Company reincorporated in Nevada. On March 15, 2012, the Company changed its name to DiMi Telematics International, Inc.

 

In early 2017, our management team elected to suspend further investment and working capital on developing its then-existing technology and business prospects, turning its attention to the hemp-derived cannabidiol, or CBD, market. On March 10, 2017, the Company changed its name to Bespoke Extracts, Inc. to align the Company’s corporate identity with its new business plan. 

 

The Company is now focused on selling its proprietary line of premium quality, all natural cannabidiol (CBD) products in the form of tinctures and capsules for the nutraceutical and veterinary markets, which it introduced in mid-2018. Produced using pure, all natural, zero-THC phytocannabinoid-rich (“PCR”) hemp-derived CBD, our products are marketed as dietary supplements and distributed through our direct-to-consumers ecommerce store, found at www.BespokeExtracts.com. In the future, we plan to also sell through select specialty retailers, pharmacies/dispensaries and care providers.

 

 

Results of Operations for the three months ended February 29, 2020 and February 28, 2019

  

Sales

 

Sales during the three months ended February 29, 2020 were $0 compared to $12,509 for the three months ended February 28, 2019. The reduction in sales was primarily a result of decreased marketing of the Company’s products.

 

Operating Expenses

 

Selling, general and administrative expenses for three month ended February 29, 2020 and three months ended February 28, 2019 totaled $190,928 and $239,560, respectively. Option and warrant expense for the three months ended February 29, 2020 and February 28, 2019 was $160,219 and $171,946, respectively which was primarily due to the fair value re-measurement of warrants and options.. Professional fees amounted to $93,411 and $68,488, respectively for the three months ended February 29, 2020 and February 28, 2019. The increase in expenses was due to increased legal fees for an offering we did not complete. Consulting expense amounted to $32,000 and $59,000 respectively for the three months ended February 29, 2020 and February 28, 2019, respectively. The decrease was primarily due to additional consultants for branding and marketing performed by consultants during the three months ended February 28, 2019 Amortization expense and impairment of domain names for the three month ended February 29, 2020 and February 28, 2019 was $1,150 and $837, respectively which was a result of amortization of domain names.

 

Loss on settlement of debt

 

On December 24, 2019, the Company entered into an agreement (the “Repayment Agreement”) with the holder of the amended and restated original issue discount convertible debenture issued by the Company on November 11, 2019, in the original principal amount of $200,000 (the “November 2019 Debenture”). Pursuant to the Repayment Agreement, the Company paid the holder $120,000, and transferred certain URLs valued at $5,282 to the holder, and the November 2019 Debenture was deemed paid in full. The amortization of debt discount of $17,843 was recorded during the three months ended February 29, 2020. The Company recognized a loss on settlement of debt of $89,595 during the three months ended February 29, 2020.

 

Interest Expense and Amortization of Debt Discount

 

Interest expense and amortization of debt discount on promissory notes for the three months ended February 29, 2020 and February 28, 2019 was $275,656 and $148,879, respectively. The increase was due to the amortization expense for the warrants and beneficial conversion associated with those notes issued into during the three months ended February 29, 2020.

 

Net Income / (Loss)

 

For the reasons stated above, our net loss for the three months ended February 29, 2020 totaled ($682,740) , or ($0.01) per share, compared to a net loss for the three months ended February 28, 2019 of ($508,535), or ($0.01) per share. 

 

 

Results of Operations for the six months ended February 29, 2020 and February 28, 2019

  

Sales

 

Sales during the six months ended February 29, 2020 were $1,739 compared to $53,940 for the six months ended February 28, 2019. The reduction in sales was primarily a result of decreased marketing of the Company’s products.

 

Operating Expenses

 

Selling, general and administrative expenses for six month ended February 29, 2020 and six months ended February 28, 2019 totaled $432,430 and $(3,838,781), respectively. Option and warrant expense for the six months February 29, 2020 and February 28, 2019 was $316,585 and $(1,629,580), respectively which was primarily due to the fair value re-measurement of warrants and options. Stock-based compensation for the six months ended February 29, 2020 and February 28, 2019 was $40,500 and $120,000, respectively which was a result of common stock issued for services. The Company recorded a gain of $(2,440,768) which was a result of a reduction in expense from forfeited common shares during the six months ended February 28, 2019. Professional fees amounted to $148,786 and $106,483, respectively for the six months ended February 29, 2020 and February 28, 2019. The increase in expenses was due to increased legal fees from an offering we did not complete. Consulting expense amounted to $133,500 and $114,500 respectively for the six months ended February 29, 2020 and February 28, 2019, respectively. The increase was primarily due to final payment of branding and marketing performed by consultants during the six months ended February 29, 2020. Amortization expense and impairment of domain names for the six month ended February 29, 2020 and February 28, 2019 was $1,986 and $1,673, respectively which was a result of amortization of domain names.

  

Financing Common Share Expense

 

Pursuant to a securities purchase agreement entered into on June 6, 2018, the Company was obligated to issue additional shares of common stock if the Company sold common stock at a price lower than $0.10 per share (or common stock equivalents with an exercise price less than $0.10 per share) during the six-month period following the closing of the purchase agreement, in which event the Company was required to issue additional shares to the purchaser for no additional consideration, such that the total number of common stock received by the purchaser would be equal to $50,000 divided by the lower financing price. During the six months ended February 28, 2019, the Company was obligated to issue 500,000 shares of common stock valued at $76,000, and recorded the amount as financing common share expense as compared to none in the comparable period in 2019.

 

Loss on settlement of debt

 

On December 24, 2019, the Company entered into an agreement (the “Repayment Agreement”) with the holder of the amended and restated original issue discount convertible debenture issued by the Company on November 11, 2019, in the original principal amount of $200,000 (the “November 2019 Debenture”). Pursuant to the Repayment Agreement, the Company paid the holder $120,000, and transferred certain URLs valued at $5,282 to the holder, and the November 2019 Debenture was deemed paid in full. The amortization of debt discount of $35,687 was recorded during the six months ended February 29, 2020. The Company recognized a loss on settlement of debt of $89,595 during the six months ended February 29, 2020.

 

Interest Expense and Amortization of Debt Discount

 

Interest expense and amortization of debt discount on promissory notes for the six months ended February 29, 2020 and February 28, 2019 was $293,500 and $232,912, respectively. The increase was due to the amortization expense for the warrants and beneficial conversion associated with those notes issued into during the six months ended February 29, 2020.

 

Net Income / (Loss)

 

For the reasons stated above, our net loss for the six months ended February 29, 2020 totaled ($1,099,145) , or ($0.01) per share, compared to a net income for the six months ended February 28, 2019 of $3,345,265, or $0.07 per share. 

 

 

LIQUIDITY AND CAPITAL RESOURCES

 

As of February 29, 2020, we had cash and cash equivalents of $45,157. Net cash used in operating activities for the six months ended February 29, 2020 was $342,686. Our current liabilities as of February 29, 2020 totaled $354,801 and consisted of accounts payable and accrued liabilities of $96,988 and a convertible note payable of $257,813, net of an unamortized discount of $242,187. As of February 28, 2019, we had cash and cash equivalents of $110,103. Net cash used in operating activities for the six months ended February 28, 2019 was $256,681.

   

During the six months ended February 29, 2020, the Company raised $125,000 from the sale of common stock compared to $285,000 for the six months ended February 28, 2019. During the six months ended February 29, 2020, the Company received a total of $400,000, net of original issue discounts of convertible note and repaid $120,000 as compared to none during the comparable six months ending February 28, 2019. During the six month ended February 29, 2020 the Company repurchased $27,500 of common stock.

 

The accompanying financial statements have been prepared assuming a continuation of the Company as a going concern. The Company had negative cash flows from operations for the six months ended February 29, 2020 and had a working capital deficit at February 29, 2020. This raises substantial doubt about our ability to continue as a going concern.

 

We have not generated positive cash flows from operating activities. Our primary source of capital has been from the sale of equity securities. Our primary use of capital has been for professional fees and general and administrative costs. We have no committed sources of capital and will need to raise additional capital to continue and expand our operations. Additional capital may not be available on terms acceptable to us, or at all.

 

In addition, the COVID-19 pandemic may negatively affect our operations, including by limiting access to our facilities, customers, management, and professional advisors. These factors, in turn, may negatively impact our operations, financial condition and demand for our products, and our ability to raise capital on acceptable terms, or at all.

  

OFF-BALANCE SHEET ARRANGEMENTS

 

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical accounting policies and estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenue and expenses during the reported periods. The more critical accounting estimates include estimates related to revenue recognition and accounts receivable allowances. We also have other key accounting policies, which involve the use of estimates, judgments and assumptions that are significant to understanding our results, which are described in Note 1 to our financial statements appearing elsewhere in this report.   

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Not required for smaller reporting companies.

 

Item 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Management of the Company conducted an evaluation of the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report.  The Company’s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and (ii) accumulated and communicated to our management, including our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Based on this evaluation, our management has concluded that the design and operation of our disclosure controls and procedures are not effective since the following material weaknesses exist:

 

●

Our chief executive officer also functions as our chief financial officer. As a result, our officer may not be able to identify errors and irregularities in the financial statements and reports;

 

●

We were unable to maintain full segregation of duties within our financial operations due to our reliance on limited personnel in the finance function. While this control deficiency did not result in any audit adjustments to our financial statements, it could have resulted in a material misstatement that might have been prevented or detected by a segregation of duties; and

 

●

Documentation of all proper accounting procedures is not yet complete.

 

To the extent reasonably possible given our limited resources, we intend to take measures to cure the aforementioned weaknesses, including, but not limited to, increasing the capacity of our qualified financial personnel to ensure that accounting policies and procedures are consistent across the organization and that we have adequate control over financial statement disclosures.

 

Changes in Internal Control over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

PART II – OTHER INFORMATION

 

 

Item 1. Legal Proceedings.

 

We are not currently a party to, nor are any of our property currently the subject of, any material legal proceedings. 

 

Item 1A. Risk Factors.

 

Not required for smaller reporting companies. 

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

None.

 

Item 3. Defaults Upon Senior Securities.

 

None.

 

Item 4. Mine Safety Disclosures.

 

No disclosure required. 

 

Item 5. Other Information.

 

None.

 

Item 6. Exhibits.

  

Exhibit No.		Description
31.1		Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*
32.1		Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Label Linkbase Document
101.PRE		XBRL Taxonomy Presentation Linkbase Document

 

*

Filed herewith.

**

Furnished herewith.

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

	BESPOKE EXTRACTS, INC.
Dated: April 9, 2020	By:	/s/ Niquana Noel
		Niquana Noel Chief Executive Officer and Chief Financial Officer
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

 

 

21